Drug Profile
TPST 1120
Alternative Names: TPST-1120Latest Information Update: 22 Apr 2024
Price :
$50
*
At a glance
- Originator Tempest Therapeutics
- Developer Roche; Sanofi; Tempest Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action PPAR alpha antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Liver cancer
- Phase I Solid tumours
- Preclinical Haematological malignancies
Most Recent Events
- 22 Apr 2024 Tempest Therapeutics plans a phase-III trial for Liver cancer (Combination therapy, First-line therapy) in Q4 2024 or Q1 2025
- 19 Apr 2024 Preclinical trials in Haematological malignancies in USA (PO)
- 09 Apr 2024 Pharmacodynamic data from preclinical studies in Cancer released by Tempest Therapeutics